CTRI/2022/09/046040已完成未知
An Open-Label Pilot Study to Evaluate the Safety and Efficacy of Zip-Stitch Surgical Wound Closure Device in the Closure of Uncontaminated Minor Lacerations
Simplified Healthcare Pvt Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Patients with Low Tension Laceration
- •2. Requires suture closure as the standard of care for simple straight wounds on trunk extremities or face.
- •3. Patients who provide a agree to abide by the study requirements
排除标准
- •1. Pregnant and lactating women
- •2. Known personal or familial history of scar hypertrophy
- •3. Known or suspected allergies or hypersensitivity to materials used in device
- •4. Atrophic skin deemed clinically prone to blistering.
- •5. Wounds that are easily susceptible to infection as a result of exposure to unsanitary conditions contaminated/dirty wounds
- •6. Wounds that require deep dermal closure using sutures.
- •7. Known or suspected psychological problems or aggressiveness that indicates that the subject might try to remove the device during the treatment period.
- •8. Ongoing treatment with cytostatic.
- •9. Known or suspected diagnosis of severe anorexia.
- •10. Currently participating or have participated in any other clinical investigation in the past 2 weeks
研究者
相似试验
进行中（未招募）
不适用
Open-Label Study to Assess Lacosamide Safety as Add-on Therapy for Primary Generalized Tonic-Clonic Seizures in Subjects With EpilepsyEpilepsyEUCTR2014-004379-22-Outside-EU/EEACB BIOSCIENCES, Inc.45
进行中（未招募）
1 期
A Pilot Open-Label Study to Investigate the Safety and Anti-inflammatory Effects of VX-765, an Orally Administered Interleukin-1ß Converting Enzyme Inhibitor, in Patients with Muckle-Wells SyndromeEUCTR2004-000283-27-GBVertex Pharmaceuticals Incorporated6
已完成
1 期
avitoclax Monotherapy and in Combination with Ruxolitinib in Myeloproliferative Neoplasm SubjectsMyeloproliferative NeoplasmJPRN-jRCT2080224824AbbVie GK9
进行中（未招募）
1 期
A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Alone and in Combination With Ruxolitinib in Participants With Myeloproliferative NeoplasmMyelofibrosis, Myeloproliferative NeoplasmsMedDRA version: 20.0Level: PTClassification code: 10028537Term: Myelofibrosis Class: 100000004864MedDRA version: 20.0Level: PTClassification code: 10077465Term: Myeloproliferative neoplasm Class: 100000004864CTIS2023-507274-40-00AbbVie Deutschland GmbH & Co. KG85
进行中（未招募）
1 期
A phase 2a trial to evaluate the safety and tolerability of LUM001 in subjects with Primary Sclerosing Cholangitis (PSC) during 14 weeks of treatment.Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease of unknown aetiology.PSC is characterized by inflammation and fibrosis of the intra- and extrahepatic biliary tree resulting in diffuse multifocal stricture formation leading to biliary cirrhosis, portal hypertension and liver failure. PSC is a life-threatening and debilitating disease. The median survival from diagnosis in symptomatic patients with PSC has been estimated to be 12 years.MedDRA version: 17.1Level: LLTClassification code 10036732Term: Primary sclerosing cholangitisSystem Organ Class: 100000004871EUCTR2014-005558-21-GBumena Pharmaceuticals LLC20